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ABSTRACT
Objectives: Patient-reported outcomes (PROs)
provide important information about the impact of
treatment from the patients’ perspective. However,
missing PRO data may compromise the interpretability
and value of the findings. We aimed to report: (1) a
non-technical summary of problems caused by
missing PRO data; and (2) a systematic review by
collating strategies to: (A) minimise rates of missing
PRO data, and (B) facilitate transparent interpretation
and reporting of missing PRO data in clinical research.
Our systematic review does not address statistical
handling of missing PRO data.
Data sources: MEDLINE and Cumulative Index to
Nursing and Allied Health Literature (CINAHL)
databases (inception to 31 March 2015), and citing
articles and reference lists from relevant sources.
Eligibility criteria: English articles providing
recommendations for reducing missing PRO data rates,
or strategies to facilitate transparent interpretation and
reporting of missing PRO data were included.
Methods: 2 reviewers independently screened articles
against eligibility criteria. Discrepancies were resolved
with the research team. Recommendations were
extracted and coded according to framework synthesis.
Results: 117 sources (55% discussion papers, 26%
original research) met the eligibility criteria. Design and
methodological strategies for reducing rates of missing
PRO data included: incorporating PRO-specific
information into the protocol; carefully designing PRO
assessment schedules and defining termination rules;
minimising patient burden; appointing a PRO
coordinator; PRO-specific training for staff; ensuring
PRO studies are adequately resourced; and continuous
quality assurance. Strategies for transparent
interpretation and reporting of missing PRO data
include utilising auxiliary data to inform analysis;
transparently reporting baseline PRO scores, rates and
reasons for missing data; and methods for handling
missing PRO data.
Conclusions: The instance of missing PRO data and
its potential to bias clinical research can be minimised
by implementing thoughtful design, rigorous
methodology and transparent reporting strategies. All
members of the research team have a responsibility in
implementing such strategies.
Patient-reported outcomes (PROs), includ-
ing health-related quality of life (HRQOL)
and speciﬁc symptoms, provide unique infor-
mation about the effect of disease and treat-
ment on the patient. PRO research evidence
is crucial for informed clinical and policy
decision-making, and is increasingly being
used to inform labelling claims for medical
products.1–3 The quality and value of PRO
evidence is contingent on a number of
factors, including: provision of a clear ration-
ale for PRO assessment, the choice of PRO
measure, the timing of PRO assessments,
and ensuring the responses are the patient’s
Strengths and limitations of this study
▪ This systematic review collates practical strategies
to minimise the problem of missing patient-
reported outcome (PRO) data. Recommendations
were retrieved from 117 multidisciplinary sources
and potential drawbacks of each recommendation
are presented.
▪ Missing PRO data may be preventable in many
cases by implementing rigorous study design
and methodological strategies, as described in
this review.
▪ In some clinical research settings, missing PRO
data is not avoidable due to deteriorating health
status of the participants. Strategies to minimise
the potential for bias caused by missing PRO
data are described.
▪ This paper discusses one aspect of PRO data
quality: data completeness. Many other factors
also contribute to high-quality PRO data, includ-
ing but not limited to appropriateness of PRO
measures, timing of PRO assessment, ensuring
patients self-complete and clinical versus statis-
tical significance of findings.
▪ This review excludes non-English sources. The
non-English publications may have been rele-
vant; however, given the repetition of themes
found in our 117 included sources we do not
believe that these would significantly affect our
findings.
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own. One critical PRO quality assurance issue is missing
data, deﬁned as “…values that are not available and that
would be meaningful for analysis if they were observed”
(ref. 4, p. 1355). Conversely, researchers may measure
‘PRO assessment compliance’, which refers to the
number of completed questionnaires received as a pro-
portion of the number expected, given the study design,
and the number of patients still alive and enrolled in
the study.5 6 Both deﬁnitions acknowledge that question-
naires are not expected from patients who have died.4–6
The practical and methodological issues associated with
missing PRO data received considerable attention in the
literature in the 1990s. An expert workshop on the preven-
tion and analysis of missing PRO data in trials led by inter-
national cancer trials groups was held in 1996, with
ﬁndings published in a dedicated special issue of Statistics
in Medicine.7 Yet problems with missing PRO data persist;
high rates of missing PRO data continue to be reported in
clinical trials,8–10 and PRO compliance rates are some-
times so poor that PRO data are not analysed.11
Persisting PRO compliance problems may reﬂect the
sporadic attention the issue has received in the literature
over the past 20 years,4 most of which is targeted to statis-
ticians handling missing PRO data during analysis. This is
problematic for four reasons: ﬁrst, content targeted at sta-
tisticians may be conceptually and technically inaccessible
to non-specialists; second, content addressing statistical
handling of missing data does not acknowledge that
some missing PRO data is preventable through study
design and implementation; third, it promotes an atti-
tude that the problem of missing data is the sole responsi-
bility of the statistician; and fourth, appropriate statistical
handling of missing PRO data is often contingent on
other research data, and this will require consideration at
the trial design stage. The broader research team should
understand the issues associated with missing data, and
their role in minimising related problems. This team
includes individuals involved in study design and plan-
ning; recruitment; data collection; quality assurance; and
analysing, interpreting or reporting of the results. To the
best of our knowledge, there has not been a systematic
review targeting the role of the broader research team in
maximising PRO compliance rates, and minimising the
problem of missing PRO data.
This paper has two aims, and is accordingly structured
in two parts:
1. To summarise the problems created by missing PRO
data in a format accessible to anyone involved in
designing, conducting or analysing clinical research.
2. To systematically review the multidisciplinary litera-
ture to identify and collate strategies relevant to the
entire research team to:
A. Maximise PRO compliance rates through study
design and implementation;
B. Reduce the potential for biased interpretation
caused by missing PRO data through PRO-
speciﬁc strategies for research design, imple-
mentation and reporting.
PART 1: THE PROBLEM OF MISSING PRO DATA—A
SUMMARY OF THE ISSUES
Missing PRO data create challenges for data analysis,
and can compromise the interpretability and value of
PRO ﬁndings for three major reasons: ﬁrst, missed
observations reduce study power.12 Studies with second-
ary PRO end points are usually sufﬁciently powered for
PRO analyses when the sample size calculation is based
on a survival primary end point (eg, progression-free
survival) because these typically require larger sample
sizes. However, a high proportion of missing PRO data
will substantially reduce power and inﬂate standard
error.13 This increases the risk of type 2 errors, that is,
false-negative ﬁndings.
Second, and more problematically, missing data may
be related to the measured outcome (ie, HRQOL, pain,
etc).12 For example, non-completers who dropped out
of Southwest Oncology Group trials due to death had
worse HRQOL at baseline, and at time of drop out than
other participants.5 In many cases, this type of missing
PRO data is unavoidable, yet it cannot be ignored as
doing so may lead to biased estimates—the extent of
which is impossible to calculate.13
Third, the presence of missing data undermines ran-
domisation, and makes intention-to-treat analyses (ana-
lysing according to randomised groups) less valid as
missing data create a need to make assumptions about
the data that are not always veriﬁable.14
Difficulties in statistically handling missing PRO data
There are many options for statistically handling missing
PRO data. Each method makes assumptions about the
missing data mechanism,15 which is a fairly technical
system for classifying missing data according to their
probable cause (see box 1). The challenge is to handle
missing data in a way that closest resembles the true,
albeit unveriﬁable, missing data mechanism, since the
mechanism often has a greater impact on research
results than does the proportion of missing data.16 To
use a simple example—if PRO data are truly missing not
at random (MNAR; eg, missing due to declining
health), but the analysis method used assumes missing
data are missing completely at random (eg, missing due
to institution error) by excluding cases with missing
data, then the analysed data represents only the better-
performing patients. Therefore, in addition to some loss
of study power, the ﬁndings may falsely indicate that
PROs are more favourable than is the true case, thus
potentially leading to biased interpretation of change
over time within groups, or of between-group differ-
ences.13 If the missing data appear MNAR, and are
handled and interpreted sensibly (within the speciﬁc
clinical and study context), the risk of introducing
bias is reduced. Although statistical approaches are
available, it is critical to prevent missing data, where
possible, rather than to rely solely on statistical
approaches. Prevention, statistical handling, interpret-
ation and transparent reporting of missing PRO data are
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complementary strategies. It is recommended that statis-
tical handling of missing PRO data be undertaken by a
statistician as the methods used are technical. Therefore,
statistical handling of missing PRO data is not addressed
in our systematic review below. Interested readers are
referred to Bell and Fairclough17 for detailed discussion.
PART 2: A SYSTEMATIC REVIEW OF STRATEGIES TO
MAXIMISE PRO COMPLIANCE RATES AND REDUCE THE
POTENTIAL FOR BIAS
Part 1 of this paper summarised the problem of missing
PRO data for the analysis and interpretation of study
results. This motivates part 2 of our paper: a systematic
review of strategies for all research team members to
assist in minimising the problem of missing PRO data.
Systematic review methods
Search strategy
MEDLINE and Cumulative Index to Nursing and Allied
Health Literature (CINAHL) databases were systematic-
ally searched using a search strategy (see online supple-
mentary appendix A) which combined PRO terms with
missing data and compliance terms. These databases
were chosen as they canvassed the disciplines of interest
to our review, and because they indexed key papers
already known to the authors. The search strategy was
developed by ﬁrst reviewing literature to identify key
search terms. We sought advice from three librarians
with expertise in systematic reviews to ensure all relevant
Medical Subject Headings (MeSH) were addressed, and
conducted several pilot searches to capture targeted
papers. The MEDLINE search was restricted to English
language articles. Reference lists and citations of
included papers retrieved in the database search were
screened (by title) for additional relevant sources, using
the same eligibility criteria.
Eligibility criteria
Papers were included if they provided guidance or
recommendations for minimising/preventing missing
PRO data in prospective research designs, or for trans-
parent interpretation and reporting of missing PRO data
to minimise risk of potential interpretation bias. We
excluded non-English articles; conference presentations;
research protocols; papers discussing statistical handling
of missing PRO data, instrument development, proxy-
reporting, patient-reported behaviours (smoking, drug
use, etc), non-patient samples and papers reporting
general study/trial drop-out rates.
Study selection
Two reviewers (RM-B and MJP) independently screened
article titles and abstracts using the eligibility criteria.
Screening discrepancies were discussed and settled with
two senior authors (MB and MTK). Abstracts that
appeared to meet the criteria were obtained in full text
and assessed against the same criteria. Our search and
study selection process complied with Preferred
Reported Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines22 (see online sup-
plementary appendix B).
Extraction and coding of recommendations
Recommendations were extracted, coded and analysed
using framework synthesis methodology (RM-B).23 24 An
a priori framework was used to organise recommenda-
tions into three categories (study design and planning,
during active study, reporting), then coded according to
the speciﬁc recommendation (eg, minimise patient
burden). These codes were reﬁned and developed
during the process, and organised into three code levels
on completion. For example, the major category of ‘min-
imise patient burden’ was subcategorised into ‘assistance
to patients’, ‘questionnaire content’, ‘length of assess-
ments’ and ‘validated questionnaires’. Each subcategory
was further categorised for speciﬁcity; for example, the
third-level categories for ‘length of assessments’ includes
‘fewer assessments’, ‘shorter questionnaire’, ‘use screen-
ing questions’, etc. Three reviewers (MTK, MJP, MB)
each checked 10% of extractions. Frequencies of each
unique recommendation were calculated, and potential
Box 1 The missing data mechanism
▸ Missing completely at random (MCAR)
The probability of missing data is unrelated to past, current
and future patient-reported outcome (PRO) scores/health
status such as administrative errors.18 MCAR assumes the par-
ticipants with missing data are a random sample of the whole
sample.18 Therefore, assuming the study is adequately
powered, the results should not be altered too much if the
MCAR are ignored in analysis; however, the standard error of
the estimates will be inflated.19 Many examples of MCAR are
caused by poor study design and implementation, and are
hence ‘preventable’ sources of missing PRO data.
▸ Missing at random (MAR)
The probability of missing data depends on observed data or a
fixed covariate, but not on the current (missing) or future PRO
scores; for example, if a particular cultural group has a high
proportion of missing data and patients from this group tend
to have poorer PRO scores.13 Depending on whether the vari-
able contributing to the likelihood of missing data is ‘inform-
ative’ (related to measured health outcome) or ‘ignorable’
(unrelated), using a statistical method that ignores MAR may
distort the findings, potentially introducing bias.19 MAR is diffi-
cult to ascertain, but methods are available to test for (albeit
with some uncertainty12 20) and analyse MAR PRO data.12 21
▸ Missing not at random (MNAR)
The probability of missing data depends on current and future
unobserved scores. PRO scores previously observed are con-
stant but would decline at (or after) drop out, and the process
of decline is not observed.18 Data that meet the MNAR
assumption are always ‘informative’, that is, missing due to
the patient’s declining health status, but the extent of decline
is not known because it is not observed. Few methods are
available for unbiased analysis of MNAR.21
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drawbacks of each recommendation were described.
Two reviewers (MJP, MTK) checked 100% of the ﬁnal
results tables. Disagreements were discussed as a team to
achieve consensus.
RESULTS
One hundred and seventeen articles (listed in online
supplementary appendix C) met the inclusion criteria
(ﬁgure 1). These arose from oncology, palliative care
and other disease-speciﬁc and non-disease-speciﬁc PRO
literature (table 1).
Design strategies to minimise the problem of missing PRO
data
Recommendations for reducing the problem of missing
PRO data through study design are summarised in 12
categories in table 2: PRO assessment schedule: a clinically
informative and feasible assessment schedule should be
deﬁned, with acceptable assessment time windows and
stopping rules; collection of auxiliary or supporting data:
collect information to facilitate unbiased interpretation
of PRO data in the presence of missing data, such
as clinician-rated health status, observational or proxy-
reported data; eligibility criteria: include literacy and lan-
guage requirements, and the need for a valid baseline
PRO assessment; feasibility issues: considerations for deter-
mining required resources and ensuring the PRO study
is feasible; guidance: for trial team members to standard-
ise administration and maximise PRO completion rates;
mode of questionnaire administration (MOA): MOA should
be feasible and acceptable, and impact on PRO comple-
tion rates should be considered; minimise participant
burden: employ strategies to ensure PRO assessment is
easy and acceptable to participants; PRO measure: PRO
measures should be clinically relevant, validated, and
acceptable to patients; PROs part of the trial: incorporate
PROs into all relevant study documents and ensure the
team is committed to the PRO study; quality assurance:
prepare databases, study guidance and procedures with
ongoing quality assurance in mind; sample: ensure the
PRO sample size is representative and sufﬁcient for
planned analyses; team involved in design/protocol develop-
ment: involve a multidisciplinary team, including PRO
experts, clinicians, nurses, site coordinators, patients
and others.
Figure 1 PRISMA flow diagram. PRO, patient-reported outcome.
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The ﬁve most frequently recommended design strat-
egies were: baseline PRO completion as an eligibility cri-
terion (n=28), develop guidance for site staff to
standardise the administration of PRO questionnaires
(n=27), minimise the length of questionnaires to reduce
patient burden (n=18), align PRO assessment time
points to clinic visits (n=16) and ensure recruiting sites
have sufﬁcient resources to run the PRO study (n=15).
Implementation strategies to minimise the problem of
missing PRO data
Recommendations for minimising the problem of
missing PRO data while the PRO study is active were
coded into seven categories in table 3: administration pro-
cedures: standardised procedures, particularly for site
staff, to maximise PRO compliance; patient education and
engagement: education about the value of PROs in the
study, and engagement through study updates or incen-
tives; maintaining patient records: contact details and
health status should be kept updated; quality assurance:
procedures and active communication to monitor com-
pliance and intervene if issues are apparent; site coordin-
ator: appoint an individual responsible for PRO
assessment at recruiting sites with appropriate organisa-
tional and communication skills; team involved in study
implementation: broader trial team must stay engaged and
committed to the PRO study, and work together towards
its successful completion; and staff training: provide
initial and ongoing training about PROs, communica-
tion skills, methodology; and formats of such training.
The most frequently recommended implementation
strategies were: use a PRO completion cover sheet for
standardised recording of reasons for missing PRO data
(n=39), appoint a site coordinator responsible for PRO
assessments (n=33), send reminders about upcoming
PRO assessments to site staff (n=30), ensure site staff
check completed PRO questionnaires for missed items
while the patient is still in the clinic (n=29) and centrally
monitor PRO compliance in real-time (n=27).
Strategies for reporting studies with missing PRO data
Strategies for reporting studies with missing PRO data
are presented in table 4. These addressed a need for
clearly reported methodology, including analysis methods;
describing the sample, including baseline scores; deﬁn-
ing and providing compliance rates; comparing participants
with and without missing PRO data; providing reasons for
missing data and discussing the impact of missing data on
generalisability of ﬁndings. The most frequently recom-
mended details to report were: rates of missing PRO
data (n=26), reasons/types of missing PRO data (n=15),
how missing data were handled for the analysis (n=9),
discussion of the potential for bias caused by missing
PRO data (n=6), and clinical and demographic
characteristics of the sample, including baseline PRO
scores (n=5).
DISCUSSION
This paper summarises the problems created by missing
PRO data, and highlights the need for all members of
the research team to assist in minimising the problem of
missing data. Our systematic review identiﬁed and
synthesised a range of practical strategies for all research
team members to maximise PRO compliance and
reduce the problem of missing PRO data through
design, implementation and reporting. These strategies
highlight the need for thoughtful planning and incorp-
oration of PROs into all research documents.25–30 PRO
study design should balance the need for sufﬁcient PRO
data with the capacity of patients to self-report, and the
feasibility and practicality of site staff to collect it at
informative time points.31–33 Previous research has
demonstrated that involving experienced data collection
personnel in PRO study development is crucial to
achieving high compliance rates.25 34 Strategies for mini-
mising bias caused by missing PRO data involve utilising
auxiliary data to inform valid analysis according to the
likely missing data mechanism; this must be planned for
during study design.
While the PRO study is active, high-level support of
the sponsor and advocacy by the PRO expert on the
research steering committee (or similar) is essential to
emphasise the importance of PRO data. Given the time-
sensitive nature of PRO data, quality assurance strategies
are crucial to maintaining high standards, particularly
real-time monitoring of PRO completion rates to enable
timely intervention if compliance falls below prespeci-
ﬁed thresholds.35 Land et al25 found that targeted
Table 1 Characteristics of included sources
N Per cent
Total 117 100.0
Disease
Cardiovascular disease 3 2.6
Non-specific 22 18.8
Oncology 65 55.6
Orthopaedics 3 2.6
Pain 2 1.7
Palliative care 6 5.1
Women’s health 3 2.6
Other 13 11.1
Publication type
Discussion/review 64 54.7
Guideline 3 2.6
Meta-analysis 2 1.7
Original research 30 25.6
Systematic review 9 7.7
Text book 6 5.1
Other 3 2.6
Year of publication (range)
1988–1989 3 2.6
1990–1999 40 34.2
2000–2009 47 40.2
2010–2015 27 23.1
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Table 2 Study design and planning strategies to minimise the problem of missing PRO data
Category
Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
Assessment
schedule
Specify PRO assessment time
points
Specify the required PRO
assessment time points
2 None Bernhard, Gusset (1998),
Beitz (1996)
Specify the minimum PRO
data requirements (eg,
‘baseline, on and off
treatment, and and/or end of
study’ (ref. 5, p. 524)
3 May create impression that
additional PRO
assessments are not
important
Bernhard, Cella (1998)
PRO assessment schedule if
treatment schedule is
disrupted (ie, will the PRO
assessment schedule be
altered if the treatment
schedule is altered?)
1 None Fairclough (2010)
Time point selection
(guidance on how to select
PRO assessment time points)
Align PRO assessments to
clinic visits so that data may
be captured while the patient
visits the clinic
16 Clinic visits may not be
most informative to capture
particular treatment effects
(eg, chemotherapy toxicity)
Bernhard, Cella (1998),
Moinpour (1998), Movsas
(2003), Aaronson (1990),
Land (2007), Walker (2003),
Calvert (2004), Sprague
(2003), Revicki (2005),
Fairclough (2010), Kyte
(2013), Blazeby (2003),
Simes (1998)
May be burdensome to
participants to attend clinic
for regular assessments
Align assessment schedule to
a fixed reference point (for
ease of calculating when PRO
assessments are due)
1 May be burdensome to
participants to attend
regular assessments
Bernhard, Cella (1998)
Allow sufficient breaks
between PRO assessments
1 May not be feasible if
investigators wish to
capture acute disease/
treatment effects or their
frequency via PROs
Sherman (2005)
Assess PROs of palliative
care patients weekly
4 Does not consider when
PRO assessment would
be most meaningful
Tang (2002)
Balance the number of
required PRO assessments
(not too few, not too many)
4 None Revicki (2005), Fairclough
(2010)
Consider patient treatment
and expected survival when
3 None Kaasa (2002), Hahn (1998),
Atherton (2006)
Continued
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Table 2 Continued
Category
Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
planning assessment
schedule (added note: avoid
PRO assessments beyond the
point of expected median
survival)
Select clinically meaningful
time points (ie, ensure that
PRO assessments will be
taken at clinically informative
times, ie, to capture the
trajectory of treatment and
recovery)
4 Clinically meaningful PRO
assessment time points
may not align with clinic
visits, which may require
alternative modes of
administration
Ganz (2007), Jordhoy (1999),
Tang (2002)
Event-driven PRO
assessment for a subsample
(ie, rather than subjecting
entire sample to detailed PRO
assessments if they
experience certain clinical
events, it may minimise staff
effort and resources to restrict
these additional assessments
to a subsample only)
2 Event-driven PRO
assessment can be
logistically challenging to
implement
Bernhard, Cella (1998),
Simes (1998)
Focus on short-term outcomes
in patients with advanced
disease (focusing on
long-term outcomes in such
samples will lead to high rates
of missing PRO data, and
uninformative data)
1 May not be clinically
meaningful to assess
short-term outcomes in all
studies
Ganz (2007)
Justify chosen PRO
assessment time points
1 None Ganz (2007)
Minimise PRO assessment
time points (select fewer time
points to minimise burden and
resource usage)
3 May sacrifice important
information by omitting
time points, for example,
differences between
treatment arms5
Bernhard, Cella (1998),
Macefield (2013), Cella
(1995)
Shorter follow-up duration
(avoid following up patients for
1 May sacrifice important
information by ceasing
Little, Cohen (2012)
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Table 2 Continued
Category
Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
a longer period of time as
participants are more likely to
drop out over time)
PRO assessment too early
in some studies. Some
studies may be interested
in long-term follow-up/
survival outcomes.
Treatment failure/cessation Continue PRO assessments
after treatment failure
6 May be difficult to engage
or contact participants
beyond point of treatment
failure
Hao (2010), Little,
D’Agnostino (2012),
Sprangers (2002), Chassany
(2002), Cella (1995), Cella
(1994)
Specify procedures for
contacting participants after
treatment cessation
3 None Cella (1994), Revicki, Hao
(2010)
Specify the PRO assessment
stopping rule (ie, under what
circumstances should PRO
assessments discontinue)
3 None Bell (2014), Kaasa (1992),
Young, de Haes (1999)
Time windows Define PRO assessment time
windows (ie, baseline
assessment time window
should always end before the
intervention/treatment
commences. Follow-up
assessment time windows
should border the period in
which treatment effects of
interest are anticipated, for
example, if the time point is
1 week postsurgery, a valid
assessment may occur
anytime between 4 and
12 days postsurgery).
12 None Bernhard, Cella (1998), Cella
(1994), Wisniewski (2006),
Blazeby (2003), Hopwood
(1996), Bernhard, Peterson
(1998), Fayers (1997),
Hopwood (1998), Revicki
(2005), Fairclough (2010),
Cella (1995)
Flexible/large time windows
(very narrow time windows
may be logistically infeasible
to implement and so risk of
missing PRO data may be
reduced by setting larger time
windows)
3 Not all time windows can
be flexible, particularly
when assessing acute
effects of treatment
Bernhard, Cella (1998), Little,
Cohen (2012), McMillan
(2003)
Continued
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Table 2 Continued
Category
Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
Collect additional/
supporting data
(which can be
used during PRO
data analysis and
interpretation)
Auxiliary data (to assist
interpretation if there are
some missing PRO data).
Suggestions of types of
auxiliary data in the next
column
Additional information about
non-responders (type of
additional information
unspecified)
1 Requires prespecification,
and additional time and
resources to collect
Kim (2004)
Clinical data 1 Requires additional time
and resources to collect
Newgard (2010)
Health status (clinician-rated
quality of life index, Karnofsky
or ECOG performance status)
6 Requires additional
clinician time
Coates (1998), Bell (2014),
Bernhard, Cella (1998),
Simes (1998), Revicki
(2005), Fairclough (2010)
Comorbidity data 1 Requires additional time
and resources to collect
Bernhard, Cella (1998)
Concomitant medications 1 Requires additional time
and resources to collect
Beitz (1996)
Observation data 1 Requires additional time
and resources to collect
Kaasa (2002)
Participant clinical data 1 None Newgard (2010)
Participant demographics 2 None Altman (2007), Newgard
(2010)
Proxy† reports when
participant is no longer able to
self-complete
21 Proxy reports are not
always concordant with
participant self-reports.
Care must be taken when
interpreting proxy data.
This is a specialist subject
and additional reading is
recommended for
investigators considering
to use proxy
assessment.64
Bernhard, Cella (1998),
Chassany (2002), Fayers
(1997), Jordhoy (2010),
Kleinpell-Nowell (2000), Kyte
(2013), Machin (1998),
Moynihan (1998), Peruselli
(1997), Revicki (2005), Rock
(2007), Simes (1998),
Sprangers (2002), Stewart
(1992), Taphoorn (2010),
Walker (2003)
Toxicity data 2 Requires additional time
and resources to collect, if
not already being collected
as part of the study
Fairclough (2010), Revicki
(2005)
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Table 2 Continued
Category
Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
Unspecified (use an
alternative to PRO in final
weeks of life)
1 Requires additional time
and resources to collect.
Additional drawbacks may
be apparent depending on
specific alternative
measure/s used.
Jordhoy (2010)
Collect reasons for missing
PRO data
– – See ‘cover sheet’ section in
administration procedures in
table 3
Eligibility criteria
for PRO study
(suggestions of
specific eligibility
or inclusion
criteria)
Consider the participants’
ability to complete PROs
Include—‘participant must be
able to complete PROs’ as an
inclusion criterion
2 Ability to complete PRO
assessments may change
over the course of
treatment. Results may not
be generalisable to all
patients.
Bernhard, Cella (1998),
Huntington (2005)
Exclude patients with
language/cognitive barriers
from the PRO study only (ie,
these participants are able to
take part in other aspects of
the trial, but will not be
included in the PRO study)
2 May reduce the sample
size/power of PRO study.
Results may not be
generalisable to all
patients.
Hopwood (1998), Sprague
(2003)
Baseline PRO completion
(some sources recommended
include baseline PRO
completion as an eligibility
criterion)
29 None Bernhard, Cella (1998),
Bernhard, Peterson (1998),
Calvert (2004), Cella (1994),
Cella (1995), Chassany
(2002), Conroy (2003),
Fayers (1997), Hayden
(1993), Hopwood (1998),
Hurny (1992), Kaasa (1998),
Movsas (2003), Osoba
(1992), Osoba (2007),
Sadura (1992), Simes (1998),
Sprangers (2002), Walker
(2003), Young, Maher (1999),
Young de Haes (1999)
Include patients with minimal
level of impairment (as per
baseline PRO) to ensure
inclusion of patients with
severe disease
1 May lead to selection bias Chassany (2002)
May impact generalisability
of results
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Table 2 Continued
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Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
Surviving long enough to
complete PROs (palliative
care)
3 Difficult to estimate in
some cases, so prognostic
cues predictive of death
may be more practical;
may introduce selection
bias.
Bakitas (2009), Jordhoy
(1999), Chassany (2002)
Participants’ willingness to
complete PROs
3 May result in selection
bias; patients more willing
to take part in PRO study
may differ systematically
from non-participants.
Fayers (1997), Sprague
(2003)
Feasibility issues
of PRO studies
Pilot study Determine feasibility of PRO
study (potential issues,
resources required and/or
sample size), and
acceptability by conducting a
pilot study
9 Requires time and
resources
Cella (1994), Cella (1995),
Groenvold (1999), Hurny
(1992), Moinpour (1989),
Kleinpell-Nowell (2000),
Young, de Haes (1999),
Sherman (2005), Wisniewski
(2006)
Determine compliance targets
by conducting a pilot study
1 Requires a long pilot study
to determine; significant
time and resources
Hahn (1998)
Conduct a pilot study to
determine average time to
complete PRO measures
1 Requires time and
resources
Kleinpell-Nowell (2000)
Use the PRO pilot study as a
training opportunity for less
experienced staff
1 Requires time and
resources
Cella (1995)
PRO resources Ensure there is sufficient
funding for the PRO study and
that the PRO study is included
in study budget
5 Funding can be difficult to
obtain; however, it is
possible to minimise costs
of PRO studies at no cost
to high-quality PRO
research
Bernhard, Cella (1998), Cella
(1995), Coates (1998), Gotay
(2005), Moynihan (1998)
Resource allocation—ensure
recruiting sites are sufficiently
resourced for the PRO study
15 Funding can be difficult to
obtain across all sites
especially if recruiting
internationally or
trans-nationally.
Bernhard, Cella (1998),
Bernhard, Peterson (1998),
Hayden (1993), Hopwood
(1998), Hopwood (1996),
Kaasa (1992), Moinpour
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Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
(1998), Moynihan (1998),
Revicki (2005), Scott (2004),
Sprague (2003), Walker
(2003), Wisniewski (2006),
Young, de Haes (1999)
Ensure adequate staff at
potential sites
2 Funding to employ new
staff can be difficult to
obtain
Revicki (2005), Scott (2004)
Minimise resources required
for the PRO study
4 Care must be taken not to
sacrifice quality of data or
performance
Bernhard, Cella (1998),
McMillan (2003)
Selection of recruiting sites Select sites with good
compliance record
1 May limit the number of
participants recruited; may
overly burden particular
sites; potential for
selection bias65
Bernhard, Cella (1998)
Select sites with adequate
resources
2 May limit the number of
participants recruited
Hurny (1992)
Sites with adequate
resources may not
necessarily be sites with
best compliance record.
Provide
PRO-specific
guidance for the
research team
PRO administration guidance
(for site staff)
General administration
guidance aiming to
standardise administration of
PROs
27 None Bernhard, Peterson (1998),
Calvert (2004), Cella (1994),
Cella (1995), Fayers (1997),
Friedman (1998), Ganz
(1988), Hahn (1998), Hayden
(1993), Hopwood (1998),
Kaasa (1998), Kaasa (1992),
Land (2007), Newgard
(2010), Osoba (1996), Osoba
(1992), Sprangers (2002),
Taphoorn (2010),
Vantongelen (1989), Walker
(2003), Wisniewski (2006)
Flexible processes across
sites (There may be local
variations in who is
1 May introduce bias if
procedures differ too much
between recruiting sites
Bernhard, Peterson (1998)
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Table 2 Continued
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Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
responsible for PRO data
collection at different sites;
therefore, procedures should
be flexible to accommodate
such differences.)
Importance of complete data
must be stressed in PRO
administration guidance
1 None Fayers (1997)
Instructions to give to
participants must be specified
in PRO administration
guidance
1 None Wisniewski (2006)
Procedures for missed
assessments must be
specified in PRO
administration guidance
1 None Calvert (2004)
Staff roles must be specified
in PRO administration
guidance
3 None Poy (1993), Young de Haes
(1999)
Procedures for handling
special situations must be
specified in PRO
administration guidance
5 Not all difficult situations
can be predicted in
advance
Hahn (1998), Hopwood
(1998), Hopwood (1996),
Revicki (2005)
Protocol guidance60 61 63 Follow PRO protocol guidance
(investigators)
2 None Bernhard, Cella (1998),
Osoba (2007)
Develop protocol guidance for
investigators (trials groups)
1 None Osoba (1996)
MOA (ie, is the
questionnaire
administered in
hardcopy (pen
and paper),
electronically, over
the phone, etc)
Choice of MOA Consider costs involved with
each MOA
1 None Macefield (2013)
Consider impact of MOA on
participants’ willingness to
disclose information
1 The most acceptable MOA
for participants may not be
the most cost-effective or
feasible
Hallum-Montes (2014)
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Table 2 Continued
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Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
Consider potential impact
MOA on response rate
3 None Hallum-Montes (2014),
Cantrell (2007)
Consider inclusion of remote
participants (web-based
modes may be more
accommodating to remote
patients than face-to-face
administration)
1 None Cantrell (2007)
Mode preferred by sample 1 Requires additional pilot
work to gauge participant
preferences. Requires
additional staff time and
costs. Need to ensure
equivalence of modes66
Basch (2012)
Electronic modes of
administration ‘e-PROs’, for
example, using a computer,
tablet, smart phone, etc
Allow participants to complete
on their preferred electronic
device
1 Requires resources to
ensure compatibility of
database across many
types of electronic devices
Jansen (2013)
Allows real-time compliance
monitoring
1 None Basch (2012)
Avoid fancy layouts 1 None Cantrell (2007)
Avoid mandating completion of
all items
2 May lead to missing
item-level data if questions
are of sensitive nature67
Cantrell (2007), Hanscom
(2002)
Present items one at a time 1 May be burdensome for
participants considering
cumulative time required to
click between screens
Hanscom (2002)
Avoid question presentation
one at a time (to reduce
response burden)
2 None Cantrell (2007),
Hallum-Montes (2014)
Dialogue boxes for missed
items
1 May be costly to develop Wisniewski (2006)
Electronic dictation of
questions
1 May be costly to develop Hallum-Montes (2014)
Email PRO assessment
reminders to participants
1 Requires time/resources to
implement
Cantrell (2007)
Continued
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Table 2 Continued
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Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
e-PROs encouraged 1 e-PRO assessment may
not be acceptable to some
patient populations.
Basch (2012)
May be subject to
technical fault/data
protection/connectivity
issues
Keep assessment simple to
reduce risk of technical fault
1 None Hjermstad (2012)
Make all items mandatory 1 May lead to incomplete
questionnaires if questions
are of a sensitive nature
Cantrell (2007)
Flexible MOA Follow-up missed
assessments with alternate
mode (eg, if participant misses
a face-to-face visit in which
hardcopy PRO assessment
was scheduled, consider
calling the participant to
complete PRO over the
phone, or posting the
questionnaire to their home
address with reply-paid
envelope to return completed
questionnaire)
4 Requires additional staff
time and resources
Bernhard, Cella (1998),
Blazeby (2003)
Interview-administered
questionnaires for very sick
participants
4 Requires additional staff
time
Kaasa (1998), Stewart
(1992), Moynihan (1998),
Chassany (2002)
Offer more than one MOA 2 May complicate data entry
procedures or procedures
for returning PRO data
Bernhard, Cella (1998),
Gotay (2005)
Negotiate with the site as to
their preferred MOA
1 May be infeasible to
implement different modes
between sites—some sites
may have to compromise
Simes (1998)
Interview-administered MOA Interview-administered MOA
may improve response rates.
1 Requires additional staff
time and resources
Fowler (1996)
Continued
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Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
Postal MOA Complete the baseline
assessment in clinic and
subsequent assessments by
post
1 None Kaasa (1998)
Include postage-paid,
self-addressed envelope for
easy return of completed
questionnaires (when using
postal MOA)
3 Requires additional staff
time and postage costs.
May be burdensome for
participants to send
questionnaires back to
researchers.
Kleinpell-Nowell (2000),
Poulter (1997)
Patient burden—
minimise
Minimise patient burden
(general statement)
8 None Aaronson (1990), Hahn
(1998), Little, D’Agostino
(2012), Macefield (2013),
McMillan (2003), Revicki
(2005), Walker (2003)
Offer assistance to
participants to complete PROs
(to reduce burden PRO
completion)
Additional assistance—
childcare (offer to provide child
care for participants’ children
so that participants can attend
clinic visits in which PRO
assessments are scheduled)
1 Requires additional
resources
Bell (2014)
Additional assistance—travel
(offer to arrange or fund travel
of participants to the clinic for
scheduled PRO assessments)
1 Requires additional
resources
Bell (2014)
Avoid the need for a clinic visit
where possible
1 May be difficult to engage
participants away from the
clinic
Little, Cohen (2012)
Offer assistance to complete
questionnaire if needed
1 Requires additional staff
time and resources
Sprague (2003)
Content Clear/simple content and
instructions of questionnaires
1 None Young, de Haes (1999)
Reduce overlap in
questionnaire items
3 None Fallowfield (1998), Walker
(2003), Young, de Haes
(1999)
Collect relevant PRO data
only
2 None Bernhard, Cella (1998), Little,
Cohen (2012)
Continued
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Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
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Supplementary Appendix C
Format Avoid using multiple
questionnaires
1 None Chassany (2002)
Avoid written (free text)
answers
1 None Friedman (1998)
Clear/simple format 6 None Conroy (2003), Little Cohen
(2012), Kleinpell-Nowell
(2000), Bernhard, Cella
(1998), Revicki (2005), Sloan
(2007)
Large/clear font 1 May increase printing
costs if larger font adds
pages to the questionnaire
booklet
Fairclough (2010)
Professional format (eg, use
study letterhead on printed
questionnaires, use consistent
formatting, etc)
3 None Kleinpell-Nowell (2000),
Revicki (2005), Sloan (2007)
Single-sided printing (some
reports suggest that
participants are more likely to
overlook the underside of
questionnaires printed
double-sided)
2 Environmental burden.
May increase printing
costs due to additional
pages in the questionnaire
booklet
Fairclough (2010), Revicki
(2005)
Uniform presentation format
(a consistent formatting
approach appears more
professional and may be
easier for participants to
follow, potentially reducing risk
of participants skipping items
inadvertently or due to lack of
understanding)
2 May not be possible if
using more than one
questionnaire
Bernhard, Peterson (1998),
Hurny (1992)
Length of assessments Consider participant health—
sicker participants will not be
able to complete long PRO
assessments
3 None Moinpour (1989), Stewart
(1992), Young, de Haes
(1999)
Fewer assessment time points
(ie, PRO assessments that
occur regularly may be overly
burdensome)
10 May sacrifice important
information by assessing
PRO less often
Bernhard, Cella (1998), Little,
Cohen (2012), Chassany
(2002), Ganz (1988), Jansen
(2013), Revicki (2005),
Continued
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Fallowfield (1998), Hurny
(1992), Hao (2010),
Steinhauser (2006)
Fewer pages in e-PROs
(eg, minimising the number of
clicks between pages may
reduce burden)
1 None Cantrell (2007)
Shorter questionnaire 18 Limits the amount of
information that can be
assessed using PROs
Basch (2012), Basch (2014),
Bell (2014), Bernhard, Cella
(1998), Bernhard, Peterson
(1998), Chassany (2002),
Fairclough (2010), Hjermstad
(2012), Hurny (1992),
Moinpour (1989), Revicki
(2005), Rock (2007), Sadura
(1992), Siddiqui (2014),
Young, de Haes (1999)
Use CAT/screening questions
(allows for targeted question
content and fewer items, to
minimise burden)
1 Requires additional set-up
costs. Can be difficult to
introduce a second,
non-electronic MOA if
using CAT as questions
administered will differ
between participants
Hjermstad (2012)
Use validated questionnaires Questionnaire items or
formatting that participants find
burdensome may be
addressed in response to
feedback obtained during
questionnaire validation
process
1 None Kaasa (1992)
Participant
education and
engagement (also
see table 3)
Continued participant
engagement—use strategies
to keep participants engaged
throughout the life of the
study/trial
Adapt procedures to
participant cultural group—
conduct background research
about the cultural groups
involved
2 Requires time and
resources
Wilcox (2001)
Participant incentives for
participating/completing PRO
questionnaires
Offer participants access to
care via/after trial/study
3 Requires time and
resources
Blazeby (2003), Little, Cohen
(2012), Little D’Agnostino
(2012)
Continued
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Offer participants financial
incentives
13 Requires time and
resources. Conflicting
evidence about the
effectiveness (in general
population samples)68 and
ethical issues in patient
populations
Dykema (2012), Gates
(2009), Jansen (2013),
Kleinpell-Nowell (2000),
Little, Cohen (2012), Meyers
(2003), Sherman (2005)
Offer participants non-financial
incentives
8 Requires time and
resources. Conflicting
evidence about the
effectiveness (in general
population samples)68 and
ethical issues in patient
populations
Dykema (2012), Little, Cohen
(2012), Sherman (2005),
Hellard (2001)
Reimburse participants for
their time/costs involved in
participating (factor into study
budget)
3 Requires time and
resources
Hellard (2001), Little, Cohen
(2012), Senturia (1998)
Selecting a PRO
measure
Acceptable measures for
participants
5 None Chassany (2002), Jordhoy
(2010), Kaasa (1992),
Revicki (2005)
Clinically relevant measures
(select PRO measures that
are clinically appropriate, that
is, include questions about
relevant issues to specific
disease/treatment)
7 None Bernhard, Cella (1998),
Friedman (1998), Ganz
(2007), Gheorghe (2014),
Hahn (1998), Revicki (2005)
Features to avoid in
prospective PRO measures
Avoid overlapping content/
highly correlated items
2 None Beitz (1996), Taphoorn
(2010)
Avoid sensitive item content
(ie, participants are more likely
to skip items addressing
sensitive issues such as
sexuality or finances; so by
avoiding such items you may
minimise risk of missing PRO
data)
4 Participants may have
different views about what
constitutes sensitive data.
Some key issues for
particular studies are
considered sensitive, for
example, sexual function
Fallowfield (1998), Jansen
(2013), Pijls-Johannesma
(2005), Simes (1998)
Translated (validated)
questionnaires
2 Complicates trial set up
and implementation,
particularly when using
e-PROs
Kaasa (1998),
Kleinpell-Nowell (2000)
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Validated measures (these
are likely to be more clinically
relevant and acceptable to
patients)
6 None Bernhard, Cella (1998),
Blazeby (2003), Fallowfield
(1998), Kaasa (1992),
Siddiqui (2014)
Other Ordering questionnaire items
chronologically may speed up
completion time and be easier
for patients to complete
1 We strongly recommend
that researchers do not
change the item order of
validated questionnaires.
Questionnaires should be
administered in the exact
format as validated.
Dunn (2003)
Strategies for measuring
sensitive issues (please see
Chassany 2002 for a
description of various
strategies)
1 None Chassany (2002)
PROs part of trial/
larger study
Research team should commit
to the PRO substudy (eg,
when part of larger trial)
11 Requires time and
resources
Bernhard, Cella (1998),
Bernhard, Peterson (1998),
Cella (1994), Cella (1995),
Chassany (2002), Hayden
(1993), Kiebert (1998),
Moynihan (1998)
Incorporate PROs in trial/main
study design
PROs should be a mandatory/
integral part of the trial/ larger
study (ie, PRO data are not an
optional extra)
10 None Aaronson (1990), Bernhard,
Cella (1998), Hayden (1993),
Hurny (1992), Kaasa (1992),
Movsas (2004), Osoba
(2007), Sadura (1992),
Siddiqui (2014), Young, de
Haes (1999)
Consider logistic factors when
designing PRO study
4 None Chassany (2002), Little,
D’Agostino (2012),
Wisniewski (2006), Young,
de Haes (1999)
PRO content in the study
protocol60 61 63
Define end points/hypotheses
(ensure PRO end point is
scientifically compelling)
5 None Cella (1994), Fallowfield
(2005), Little, Cohen (2012),
Taphoorn (2010), Walker
(2003)
Specify how missing data will
be handled
1 May not be possible to
fully plan how missing data
Calvert (2004)
Continued
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will be handled
prospectively
Specify the importance of
PRO assessment compliance
1 None Fayers (1997)
Include/plan PRO aspects of
the study carefully
13 None Bell (2014), Fayers (1997),
Ganz (2007), Hahn (1998),
Hao (2010), Land (2007),
Moinpour (1998), Movsas
(2003), Poy (1993), Revicki
(2005), Sloan (2007),Walker
(2003)
Specify plans for minimising
missing data (such as those
listed in this review) in the
protocol
11 None Beitz (1996), BIQSFP (2012),
Calvert (2004), Fairclough
(2010), Kaasa (1998),
Moinpour (1998), Revicki
(2005), Simes (1998), Young,
de Haes (1999)
Specify PRO assessment
schedule
2 None Hopwood (1996), Moinpour
(1998)
Specify the rationale for PRO
assessment (understanding
why PROs are being
measured and the value the
information will bring to the
trial is useful for all members
of the trial team, and
reinforces the importance of
high-quality PRO data
collection)
11 None Aaronson (1990), Bell (2014),
Cella (1994), Cella (1995),
Conroy (2003), Fayers
(1997), Hopwood (1998),
Sadura (1992)
Include PROs in
the SAP†
Specify potential problems
with PRO analysis in SAP
2 May not be possible to
predict and prepare for all
potential problems with
PRO analysis when
developing the SAP
Taphoorn (2010), Walker
(2003)
Plans for addressing missing
data in SAP
2 May not be possible to
fully plan how missing data
will be handled
prospectively
Bell (2014), Bernhard,
Peterson (1998)
PROs in other trial/study
documents
1 None Land (2007)
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Table 2 Continued
Category
Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
Include PRO study in relevant
sections of procedural
documents
QA QA—planning ahead Consider logistic factors when
designing PRO study
1 None Fallowfield (2005)
Create study databases with
QA in mind (ie, consider how
PRO data completion rates will
be monitored using the
database)
5 Requires time and
resources
Bernhard, Cella (1998), Land
(2007), Moinpour (1998),
Wisniewski (2006)
Manage PROs with other trial/
study end point data (ie, in a
single database)
2 Data managers will require
additional training for
PROs—which requires
additional time and
resources
Bernhard, Peterson (1998),
Hurny (1992)
Describe QA procedures in
protocol
3 None Cella (1995), Gheorghe
(2014), Revicki (2005)
Specify QA procedures in a
manual
2 None Cella (1994),Cella (1995)
Establish target PRO
compliance rates (ie, quotas
that must be achieved, eg, a
target of 95% indicates that no
more than 5% of missing PRO
questionnaires will be
tolerated)
6 None Hahn (1998), Little, Cohen
(2012), Little, D’Agostino
(2012), McMillan (2003),
Sloan (2007)
Sample (for PRO
data collection)
PRO subsample (if study
power permits and if the study
budget or logistics limit
capacity to collect PROs from
all participants, consider
collecting PROs from a
subsample only)
PRO data from representative
subsample of the trial
population
2 May be difficult
administratively,
particularly for site staff to
implement
Simes (1998)
Do not collect PROs from
patients with advanced
disease
1 QOL issues are often of
very important in patients
with advanced disease.
Bernhard, Cella (1998)
Allow patients/sites to opt in to
the PRO study
1 Simes (1998)
Continued
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Table 2 Continued
Category
Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
May lead to selection bias
if sites or participants
opt-in to PRO study
May also lead to
impression that PRO study
is of lesser importance
than other study outcomes
Recruit motivated patients
only
2 May lead to selection bias if
only motivated participants
take part in PRO study
Bernhard, Cella
(1998), Simes
(1998)
Separate (additional) consent
for PRO study
1 Requires additional time
and resources
Simes (1998)
Sample size Increase sample size to allow
for attrition
7 The rate of missing data is
important, regardless of
whether the available data
meet sample size
requirements. Although
increasing sample size will
improve study power in the
case of low PRO
completion rates, the
outcomes of participants
with missing PRO data
may differ to those with
complete PRO data—
which may lead to bias.
Altman (2007), Kaasa (2002),
Little, D’Agostino (2012),
Sherman (2005), Stewart
(1992), Tang (2002), Jordhoy
(2010)
Team—design/
protocol
development
Involve committees (to review
PRO study)
Ethics review 1 None Movsas (2003)
PRO committee (ie, some
trials groups have a dedicated
PRO committee, comprised of
PRO research specialists who
review and provide feedback
on PRO aspects of trials)
6 Requires access to a trials
group with resources for a
PRO committee
Hahn (1998), Osoba (1992),
Osoba (2007), Revicki (2005)
Continued
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Table 2 Continued
Category
Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
Multidisciplinary team involved
in design/protocol
development (each party
brings unique and
complementary expertise and
experiences to improve the
design of the PRO study)
Involve a multidisciplinary
team in PRO study design
6 None Bernhard, Cella (1998), Cella
(1994), Cella (1995), Kiebert
(1998), Moinpour (1998)
Involve experienced
investigators in PRO study
design (to offer strategies for
maximising compliance,
selection of informative
measures and time points,
and other key aspects of study
design)
2 None Little, Cohen (2012), Little,
D’Agostino (2012)
Involve nurses in PRO study
design (to offer expertise
about patient experiences and
relevant QOL issues, clinic
environment, data collection,
etc)
1 None Hayden (1993)
Involve patients in PRO study
design (to comment on the
acceptability and relevance of
PRO questionnaires, suitability
of assessment time points in
capturing desired outcomes,
patient burden, strategies to
educate and engage
participants, and many other
important aspect of study
design)
3 None Bernhard, Peterson (1998),
Hurny (1992), Moynihan
(1998)
Involve PRO experts in PRO
study design (to offer
strategies for maximising
compliance, selection of
informative measures and time
points, analysis and
interpretation strategies and
3 None Fallowfield (1998), Kiebert
(1998), Basch (2014)
Continued
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Table 2 Continued
Category
Design Topic Specific recommendation N recommendations* Potential drawbacks
Source/s: first author
(year). Full citations are
provided as Online
Supplementary Appendix C
other key aspects of study
design)
Involve site coordinators in
PRO study design (to offer
expertise about logistics of
PRO assessment, patient
experiences and relevant QOL
issues, data collection
strategies, etc)
4 None Bernhard, Cella (1998),
Hayden (1993), Larkin
(2012), Moinpour (1998),
Cella (1995)
Support the site staff Minimise institution/staff
burden (an overly burdensome
PRO assessment schedule or
procedure for site staff is likely
to lead to high rates of missing
data)
6 None Aaronson (1990), Young, de
Haes (1999)
*Some sources may have provided a recommendation more than once.
†This review only covers proxy reporting as a strategy to facilitate interpretation of missing PRO data. If considering using proxies, please consult the literature for a review of additional
challenges and implementation strategies.
CAT, computer-adaptive testing; ECOG, Eastern Cooperative Oncology Group; ePRO, PROs administered electronically; MOA, mode of administration; PRO, patient-reported outcome;
QA, quality assurance; QOL, quality of life; SAP, statistical analysis plan.
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Table 3 Study conduct strategies to minimise the problem of missing PRO data
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Administration
procedures
Approach all participants All participants involved in the
PRO study should be
approached to complete
scheduled PRO assessments,
including those who are very ill
(Site staff should not make any
decisions about who is able to
complete PROs as this may
lead to selection bias. The
decision is the participant’s.)
11 None Bernhard, Peterson (1998),
Fairclough (2010), Hopwood
(1998), Bakitas (2009),
McMillan (2003), Revicki
(2005), Young, de Haes
(1999), Aaronson (1990),
Moynihan (1998)
Assistance completing
PRO measures
Prespecify types/levels of
assistance that may be
provided to participants
5 None Fayers (1997), Kaasa (2002),
Revicki (2005), Young, de
Haes (1999), Fairclough
(2010)
Offer assistance to participants
who need it
11 Requires additional staff time Aaronson (1990), Bernhard,
Peterson (1998), Fayers
(1997), Friedman (1998),
Hurny (1992), Jordhoy (2010),
Bakitas(2009), Macefield
(2013), Repetto (2001),
Young, de Haes (1999)
Record levels of assistance
provided
1 None Blazeby (2003)
Nominate who should provide
assistance to participants
3 Requires additional time and
resources
Cella (1995), Revicki (2005),
Young, de Haes (1999)
Be organised Ensure sufficient
questionnaires available for
use
1 None Moynihan (1998)
Prepare for upcoming
assessments (have
questionnaires ready)
6 None Vantongelen (1989), Cella
(1995), Coates (1998),
Moinpour (1989), Revicki
(2005), Young, de Haes
(1999)
Prepare to handle potential
problems
1 None Revicki (2005)
Track when PRO assessments
due
5 None Cella (1994), Cella (1995),
Young, de Haes (1999)
Checking Checking for missed PRO
items
29 None Calvert (2004), Cella (1994),
Cella (1995), Chassany
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
(2002), Davies (1994),
Fallowfield (1998), Fayers
(1997), Fowler (1996),
Friedman (1998), Ganz
(1988), Hayden (1993),
Hopwood (1998),
Kleinpell-Nowell (2000), Kyte
(2013), Moinpour (1990),
Moinpour (1998), Movsas
(2003), Movsas (2004),
Revicki (2005), Taphoorn
(2010), Wisniewski (2006),
Young, de Haes (1999)
Checking source data (data
entry; when entering
questionnaire data into
database)
2 None Davies (1994), Poy (1993)
Ensure patients receive
questionnaires (particularly
when the patients complete
questionnaires outside of
clinic)
1 None Kaasa (1998)
PRO completion cover
sheet (a form on which
site staff can record
whether PROs were
completed and if not
completed, the possible
reason why)
Importance of cover sheet 1 None Moinpour (1998)
Recording levels of assistance 6 Requires additional time and
resources to collect
Fayers (1997), Fairclough
(2010), Fayers (1997),
Moinpour (1998), Hopwood
(1998), Revicki (2005)
Standardised reasons for
missing data (possible reasons
for non-completion of PROs
may be listed on a cover sheet
for the convenience of site staff
and for ease of data collection)
39 Requires additional time and
resources to collect
Fairclough (2010), Fayers
(1997), Moinpour (1998),
Hopwood (1998), Revicki
(2005), Bell (2014), Bernhard,
Cella (1998), Blazeby (2003),
Calvert (2004), Curran (1998),
Reasons for missing PRO data
may not be easy to determine in
some cases.
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Fairclough (2010), Fallowfield
(1998), Fayers (1997), Hahn
(1998), Hao (2010), Kiebert
(1998), Kleinpell-Nowell
(2000), Land (2007), Little,
Cohen (2012), Luo (2008),
Moinpour (1990), Moinpour
(1998), Revicki (2005), Simes
(1998), Taphoorn (2010),
Walker (2003), Wisniewski
(2006), Young, de Haes
(1999)
Missed assessments Alternative mode of
administration (if participants
miss a PRO assessment,
contact the participant to
capture the data using an
alternative mode. Also see
table 2 ‘Mode of
administration’)
17 Requires additional staff time and
resources. Potential for bias
based on setting of completion
(systematic differences between
modes, particularly if one mode
is interview administered, and the
other is completed by patient66)
Basch (2014) Calvert (2004),
Cella (1995), Fairclough
(2010), Fowler (1996),
Hopwood (1996), Hurny
(1992), Kleinpell-Nowell
(2000), Land (2007),
Moinpour (1990), Revicki
(2005), Stewart (1992),
Walker (2003), Revicki (2005)
Following up missed
assessments
18 Requires additional staff time and
resources
Cella (1994), Cella (1995),
Conroy (2003), Fowler (1996),
Hopwood (1998), Huntington
(2005), Kleinpell-Nowell
(2000), Movsas (2003),
Movsas (2004), Sherman
(2005), Sprague (2003),
Sprangers (2002), Taphoorn
(2010), Wisniewski (2006),
Young, de Haes (1999)
Specify place of PRO
completion (eg, quiet spot
in the clinic)
8 May be difficult to offer a quiet
place to complete questionnaires
in busy clinic environment
Calvert (2004), Hurny (1992),
Jansen (2013), Moynihan
(1998), Sadura (1992),
Sherman (2005), Young, de
Haes (1999)
Returning questionnaires Specify procedures for
returning questionnaires
1 None Poulter (1997)
Continued
28
M
ercieca-Bebber
R,etal.BM
J
Open
2016;6:e010938.doi:10.1136/bm
jopen-2015-010938
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 O
ctober 14, 2016 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Time of completion Standardise time of completion
(eg, first thing when the patient
arrives at the clinic)
2 None Bernhard, Cella (1998),
Fayers (1997)
Before seeing clinician (many
sources recommended PROs
should be completed before
the participants have their
appointment with their
clinician)
4 Requires advanced planning and
potential negotiation with clinician
to ensure PRO assessment is
complete prior to the clinic
appointment. Difficulties may
arise if scheduled PRO
assessments do not align with
clinic visits.
Fayers (1997), Sprague
(2003), Young, de Haes
(1999), Hopwood (1998)
Standardised methods Adhere to PRO assessment
schedule
2 None Moinpour (1998), Poulter
(1997)
Use standard administration
methods
5 None Cella (1995), Chassany
(2002), Movsas (2003),
Movsas (2004), Revicki
(2005)
Standardise methods (eg, by
developing written guidance)
13 Time and minimal costs involved
initially
Bernhard, Gusset (1998),
Cella (1995), Chassany
(2002), Fayers (1997),
Gheorghe (2014), Hopwood
(1998), Moinpour (1998),
Movsas (2003), Movsas
(2004), Osoba (2007), Poy
(1993), Revicki (2005),
Sadura (1992)
Thank the participant On completion of questionnaire
(face-to-face)
6 None Calvert (2004), Kyte (2013),
Meyers (2003), Sherman
(2005), Steinhauser (2006),
Young, de Haes (1999)
Thank you letters 3 Requires additional time and
resources
Steinhauser (2006),
Fallowfield (1998), Poulter
(1997)
Train staff – – See ‘Train staff’ category
Participant
education and
engagement
Confidentiality Be mindful of sensitive PRO
data (ensure participants
understand it will be kept
confidential)
2 None Cella (1994), Sherman (2005)
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Discuss family involvement
(participants may not wish to
disclose certain information if
they believe family members
may see the data)
1 None Sherman (2005)
Inform participants that PRO
data are kept confidential
6 None Calvert (2004), Fallowfield
(1998), Movsas (2003),
Sherman (2005), Simes
(1998), Young, de Haes
(1999)
Sealed envelopes (allow
participants to self-seal so they
are assured of the
confidentiality of data)
1 Prevents site staff from being
able to check for any missing
items
Fallowfield (1998)
Strategies for continued
participant engagement
Site staff should offer to
answer participant questions
3 None Calvert (2004), Fayers (1997),
Hurny (1992)
Awareness of culturally
sensitive issues
1 None Bernhard, Cella (1998)
Match staff to participant
cultural group (Some
participants may build rapport
more easily if they liaise with a
coordinator from the same
cultural group.)
1 May not be possible/feasible for
all studies
Cella (1995)
Build rapport with participants 4 None Blazeby (2003), Steinhauser
(2006)
Educate participants about
PROs (importance of PROs,
how PRO data are used, how
to complete PROs)
5 Requires staff time and
commitment—depending on the
comprehensiveness of education
offered
Basch (2012), Fairclough
(2010), Gotay (2005),
Huntington (2005), Kaasa
(1998)
Provide clear/simple
instructions for completion of
PRO assessments
5 None Bernhard, Peterson (1998),
Calvert (2004), Chassany
(2002), Hurny (1992), Revicki
(2005)
Encourage participants to ask
for questionnaire when they
are due (in case site staff
forget)
2 None Fayers (1997), Hopwood
(1998)
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Ensure participants understand
(PRO assessment/how to
complete questionnaires, etc)
8 Requires staff time, Moinpour (1990), Moinpour
(1998), Muller-Buh (2011),
Poulter (1997), Revicki (2005)
Collect information about
participants at risk of dropping
out and use that information to
intervene, or implement
intensive follow-up strategies
for these participants
4 Risk of drop out may be difficult
to predict in some samples.
Little, D’Agostino (2012),
Senturia (1998),Sprague
(2003)
Maintain contact with
participants
4 Requires staff time, resources
and commitment
Hellard (2001),
Kleinpell-Nowell (2000),
Senturia (1998), Wisniewski
(2006)
Send participants PRO
assessment reminders
16 Requires staff time, resources
and commitment
Altman (1993), Basch (2012),
Bell (2014), Bernhard, Cella
(1994), Cella (1995), Cella
(1998), Fallowfield (1998),
Jansen (2013),
Kleinpell-Nowell (2000), Land
(2007), Revicki (2005),
Sherman (2005), Sprague
(2003), Wisniewski (2006)
Provide assistance to
participants when required
1 Requires staff time, resources
and commitment
Fairclough (2010)
Provide encouragement to
participants when completing
PROs
4 Requires staff time, resources
and commitment
Basch (2012), Bernhard, Cella
(1998), Little, Cohen (2012),
Revicki (2005)
Explain reason for multiple
PRO assessments
4 None Bernhard, Peterson (1998),
Calvert (2004), Hurny (1992),
Sprague (2003)
Explain and remind
participants of importance of
PROs
11 None Fayers (1997), Kyte (2013),
Taphoorn (2010), Wilcox
(2001), Calvert (2004), Cella
(1995), Chassany (2002),
Conroy (2003), Hellard
(2001), Sherman (2005)
Update participants on trial/
study progress
6 Requires staff time, resources
and commitment
Cella (1995), Hellard (2001),
Little, Cohen (2012), Sadura
(1992)
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Informed consent (ensure
these aspects of PRO
study are addressed)
Instruct participants to answer
honestly/no right or wrong
answers
1 None Young T, de Haes (1999)
Inform participants that
assistance is available if
needed
1 None Young T, de Haes (1999)
Explain commitment involved
for the PRO study
7 None Bernhard, Cella (1998),
Blazeby (2003), Hurny (1992),
Sherman (2005), Sprague
(2003), Young, de Haes
(1999)
Explain PRO assessment
during informed consent
process
5 None Fallowfield (1998), Fayers
(1997), Hopwood (1998),
Movsas (2003), Moynihan
(1998)
Explain importance of PRO
assessment
14 None Bernhard, Cella (1998),
Conroy (2003), Fairclough
(2010), Fayers (1997),
Friedman (1998), Hurny
(1992), Kleinpell-Nowell
(2000), Blazeby (2003),
Revicki (2005),Taphoorn
(2010), Walker (2003), Young,
de Haes (1999)
Explain importance of
complete PRO data
5 None Bernhard, Peterson (1998),
Little, Cohen (2012), Young T,
de Haes (1999),
Kleinpell-Nowell (2000),
Revicki (2005)
Explain that participation is
voluntary
1 None Sherman (2005)
Language translations
available (participants may feel
more confident using an
alternative language translation
that the default language
offered)
1 None Young T, de Haes (1999)
Ensure participant understands 3 None Ganz (1988), Young, de Haes
(1999)
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Participants can take
information sheets home.
3 None Fayers (1997), Land (2007)
Recruitment method Face-to-face recruitment 2 None Jansen (2013)
Follow the recruitment protocol 1 None Senturia (1998)
Less aggressive recruitment
methods may be more
effective than more assertive
methods.
2 May result in reduced
recruitment. Recruitment method
should not be aggressive, not
lax.
Hellard (2001), Kaasa (1998)
Participant
records
Obtain contact details at
registration
Alternate contact (a close
relative or friend who you can
contact in case the participant
cannot be reached)
5 Some participants may not have
a trusted friend/relative to
nominate as alternate contact.
Alternate contact person will
need to provide consent to be
contacted—which may be difficult
to obtain and/or implement.
Kleinpell-Nowell (2000),
Senturia (1998), Sherman
(2005)
Obtain complete participant
contact details
1 Participant contact details may
change during the course of the
study; therefore, contact details
should be checked regularly.
Sprague (2003)
Specify procedures for
checking and updating
participant records
3 None Cella (1995), Moinpour
(1990), Senturia (1998)
Update participant records Check if participant is alive (It
may be distressing for friends/
family members if study
reminder letters are posted to
participants home after they
have died. This situation can
be avoided by contacting the
participant’s doctor for updates
on the participant’s condition.)
2 Must be handled carefully if
participants’ relatives are
contacted, and may require
formal approval if participants’
GPs are contacted
Fallowfield (1998), Hopwood
(1996)
Update participant contact
details
6 Requires time and resources Kleinpell-Nowell (2000), Little,
Cohen (2012), Little,
D’Agostino (2012), Meyers
(2003), Young, de Haes
(1999)
Record successful strategies
for contacting participants (so
that these strategies may be
used for future study contact)
1 None Meyers (2003)
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Quality
assurance
Central monitoring for
PROs
Central office monitors
compliance
4 Requires planning and resources
to implement
Bernhard, Cella (1998),
Hayden (1993), Kiebert
(1998), Land (2007)
Appoint a central PRO
coordinator/QA officer
12 Requires additional resources Bell (2014), Bernhard, Cella
(1998), Cella (1994), Cella
(1995), Fallowfield (1998),
Hahn (1998), Hurny (1992),
Land (2007), Moinpour
(1990), Poy (1993), Simes
(1998), Sloan (2007)
Real-time monitoring of PRO
completion (enables prompt
intervention if PRO
assessments are missed)
27 Requires time, commitment and
resources of site and central
monitoring staff. Requires input
from database developers and
statisticians from set-up phase.
Difficult to implement for multisite
trials due to delays in obtaining
PRO forms from sites, and
differences between patients in
recruitment time
Basch (2012), Basch (2014),
Bernhard, Cella (1998),
Bernhard, Gusset (1998),
Bernhard, Peterson (1998),
Ganz (2007), Hayden (1993),
Huntington (2005), Kyte
(2013), Little, Cohen (2012),
Movsas (2003), Poy (1993),
Revicki (2005), Siddiqui
(2014), Sprague (2003),
Walker (2003), Wilcox (2001),
Wisniewski (2006), Young, de
Haes (1999)
Communication Central monitors should
discuss participants who
withdraw with site staff (this
may identify potential issues
with site management and
potential strategies for avoiding
problems in future).
1 Requires real-time compliance
monitoring, which requires time,
commitment and resources of
central and site staff
Sprague (2003)
Discuss the role of site staff in
responding to participants’
medical needs
1 None Sherman (2005)
Central office should send
feedback reports to sites on
PRO compliance and reasons
for missing PRO data (this may
assist sites to recognise
problematic patterns in missing
14 Requires real-time compliance
monitoring, which requires time
and resources of central staff
Bernhard, Peterson (1998),
Bernhard, Cella (1998), Land
(2007), Friedman (1998),
Hahn (1998), Hurny (1992),
Senturia (1998), Wilcox
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
data, and to work towards
rectifying such issues).
(2001), Young, de Haes
(1999), Young, Maher (1999)
Sites should send feedback to
central office (problems,
participant feedback, etc,
which may be able to be
addressed through discussion,
in future protocol amendments
or in future studies)
3 Time commitment Bernhard, Gusset (1998),
Hopwood (1998)
Importance of regular
communication between
research team
20 Requires time and resources Bernhard, Peterson (1998),
Calvert (2004), Cella (1994),
Cella (1995), Hayden (1993),
Land (2007), Moinpour
(1998), Moynihan (1998),
Osoba (1992), Poy (1993),
Wisniewski (2006), Young, de
Haes (1999)
Regular meetings (a forum for
communication between the
research team)
6 Requires time and resources Cella (1994), Land (2007),
Moinpour (1989), Osoba
(1996), Sprague (2003),
Wisniewski (2006)
Share strategies for successful
PRO compliance
3 None Bernhard, Peterson (1998),
Calvert (2004),
Kleinpell-Nowell (2000)
Schedule when reports are due
for the sites to communicate
with the central office
1 None Cella (1995)
Reward high performing
sites/staff
Document methods of success
(regarding high PRO
completion rates)
1 None Stewart (1992)
Offer financial incentives to
sites for high completion rates
5 Costs involved Little, D’Agostino (2012),
Ganz (2007), Little, Cohen
(2012), Aaronson (1990),
Bernhard, Gusset (1998)
Offer incentives to sites for
high completion rates (type of
incentive unspecified)
4 Costs involved Basch (2012), Bernhard, Cella
(1998), Cella (1995), Hurny
(1992)
Offer National Cancer Institute
(NCI, USA) credit as incentive
2 Costs involved Land (2007)
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Offer non-financial incentives 1 Costs involved Little, D’Agostino (2012)
Site coordinator authorship as
incentive
1 Costs involved Moinpour (1998)
Thank you letters to site staff 1 Time and costs involved Land (2007)
Travel support to high
performing site staff as
incentive
2 Costs involved Hahn (1998)
Poorly performing sites Intervene in poorly performing
sites (ie, with additional
training, discussion about
support needed to improve
completion rates, etc)
4 Requires real-time compliance
monitoring, and time and
resources to implement
interventions
Bernhard, Gusset (1998),
Hahn (1998), Hahn (1998),
Land (2007)
Introduce incentives if
improvement is seen at poorly
performing sites
1 Costs involved. Need to be
introduced before compliance
rates fall too low.
Cella (1994)
Penalise sites for poor
compliance (eg, eliminate
opportunity for future
recruitment/involvement in
future trials)
5 May reduce morale at that site if
not handled appropriately
Bernhard, Cella (1998),
Hayden (1993), Land (2007),
Moinpour (1998)
Terminate recruitment at poorly
performing sites
2 May reduce number of patients
eligible for recruitment
Fayers (1997), Poy (1993)
QA should be in place to
promote high completion
rates
– 10 Requires commitment and
resources to implement
Bell (2014), Bernhard, Cella
(1998), Bernhard, Peterson
(1998), Cella (1995),
Moinpour (1989), Moinpour
(1998), Osoba (2007), Poy
(1993), Revicki (2005)
Rate site’s performance
and assess against
benchmark compliance
rates
1 Requires real-time compliance
monitoring, which requires central
staff time and resources
Land (2007)
Site-level monitoring Sites should be prepared for
regulator inspections
1 Requires time and commitment of
site and central staff
Poy (1993)
Sites should also monitor their
own compliance rates
1 Requires time and resources Hahn (1998)
Support for sites/staff Offer ongoing training to site
staff
4 Time and costs involved Cella (1994), Cella (1995),
Hahn (1998), Revicki (2005)
Continued
36
M
ercieca-Bebber
R,etal.BM
J
Open
2016;6:e010938.doi:10.1136/bm
jopen-2015-010938
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 O
ctober 14, 2016 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Send site staff reminders (for
upcoming/overdue PRO
assessments)
32 Requires time and resources Basch (2012), Bernhard, Cella
(1998), Bernhard, Peterson
(1998), Cella (1994), Cella
(1995), Fairclough (2010),
Hahn (1998), Hayden (1993),
Hurny (1992), Land (2007),
Moinpour (1989), Moinpour
(1998), Osoba (1992), Poulter
(1997), Revicki (2005),
Sadura (1992), Siddiqui
(2014), Simes (1998),
Vantongelen (1989)
Site coordinator Appoint a site coordinator
—an individual at each
site responsible for PRO
administration for the
study
34 Costs involved Beitz (1996), Bernhard, Cella
(1998), Bernhard, Peterson
(1998), Blazeby (2003),
Calvert (2004), Cella (1994),
Cella (1995), Conroy (2003),
Fallowfield (1998), Fayers
(1997), Ganz (1988), Gotay
(2005), Hahn (1998), Hayden
(1993), Hopwood (1998),
Hurny (1992), Kaasa (1992),
Kyte (2013), Moinpour (1989),
Moinpour (1990), Muller-Buh
(2011), Poulter (1997),
Revicki (2005), Stewart
(1992), Young, de Haes
(1999)
Roving coordinator (Rural/
remote centres may have too
few participants to warrant
appointing a dedicated site
coordinator. Instead a roving
coordinator may be responsible
for several such sites.)
1 Costs involved Scott (2004)
May be difficult to implement if
rural centres are geographically
distant, and if participants have
similar PRO assessment
schedules
Nominate a back-up site
coordinator (If a primary site
coordinator is absent, this
3 Requires additional resources to
ensure back-up coordinator is
adequately trained and informed
about the PRO study
Calvert (2004), Fayers (1997),
Revicki (2005)
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
individual will take
responsibility for the trial.)
Characteristics of site
coordinator
Committed to the study 2 None Blazeby (2003), Larkin (2012),
Moinpour (1998)
Site staff should be
accommodating/flexible
7 The flexibility of site staff is
limited by their individual
schedules and the resources
available at the site
Senturia (1998), Sherman
(2005), Sprague (2003)
Interpersonal skills 1 Interpersonal skills cannot always
be taught
Bernhard, Cella (1998)
Languages spoken (if the site
has participants from multiple
language backgrounds, it may
be crucial to employ a
coordinator who can speak
these language/s)
1 May be difficult to recruit
multilingual site coordinators
Bernhard, Peterson (1998)
Positive attitude 8 Difficult to train staff to have a
positive attitude. Ascertaining
and intervening in such problems
may be difficult to implement.
Bernhard, Cella (1998),
Fairclough (2010), Kaasa
(1992), Larkin (2012), Revicki
(2005), Scott (2004),
Sherman (2005)
Team involved in
study
implementation
Commitment to the PRO
study—required of the
entire trial team,
specifically:
Central office staff 1 May require some education
about the value and importance
of complete PRO data—which
may require additional time and
resources
Osoba (2007)
Physicians 2 May require some education
about the value and importance
of complete PRO data—which
may require additional time and
resources
Hurny (1992), Vantongelen
(1989)
Multidisciplinary support 2 May require some education
about the value and importance
of complete PRO data—which
may require additional time and
resources
Poy (1993)
Site coordinators 3 May require some education
about the value and importance
of complete PRO data—which
may require additional time and
resources
Larkin (2012), Hayden (1993)
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
Participants 1 May require some education
about the value and importance
of complete PRO data—which
may require additional time and
resources
Hayden (1993)
Sponsor 1 May require some education
about the value and importance
of complete PRO data—which
may require additional time and
resources
Poy (1993)
PRO Committee (group of
PRO experts involved with a
trials group who liaise with and
advise trial investigators about
PRO research. Committees
may review PRO aspects of
protocols or may be
represented on trial teams69)
2 May require additional time and
resources
Hahn (1998), Osoba (1992)
Support the site staff Offer support to sites/staff (eg,
psychological support,
bereavement counselling)
6 Requires time and resources Wilcox (2001), Sherman
(2005), Steinhauser (2006)
Minimise institution burden 6 None Aaronson (1990), Young, de
Haes (1999)
Offer a flexible working
environment for site staff
1 Needs to be negotiated within the
needs of the PRO study
Steinhauser (2006)
Reward site staff for their work 2 Needs to be negotiated within the
resources of the study
Steinhauser (2006)
Train staff Train site staff Training for site coordinators is
needed
27 Requires time and resources Basch (2012), Bernhard, Cella
(1998), Bernhard, Gusset
(1998), Bernhard, Peterson
(1998), Cella (1995),
Fairclough (2010), Ganz
(2007), Gotay (2005), Hahn
(1998), Hopwood (1998),
Huntington (2005), Hurny
(1992), Movsas (2003),
Movsas (2004), Moynihan
(1998), Osoba (1996), Poulter
(1997), Poy (1993), Revicki
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
(2005), Sherman (2005),
Vantongelen (1989), Walker
(2003)
Booster/ongoing training
should also be offered,
particularly if the trial/study
runs over many years and staff
changeover is expected.
15 Requires time and resources Bernhard, Cella (1998),
Bernhard, Peterson (1998),
Cella (1994), Cella (1995),
Hahn (1998), Larkin (2012),
Moinpour (1998), Revicki
(2005), Wilcox (2001),
Wisniewski (2006), Young, de
Haes (1999), Young, Maher
(1999)
Poorly performing sites—
additional training should be
offered to help improve
compliance rates in future
3 Requires central monitoring to
identify poorly performing sites
+time/resources to implement
training
Fayers (1997), Hopwood
(1998), Poy (1993)
Content of training for trial
staff—the following issues
related to PROs should be
addressed:
Communication skills
(particularly for site
coordinators—good
communication skills are
essential for ensuring the PRO
study is explained to
participants, ensuring
participants’ questions are
answered, and for building
rapport)
5 Requires time and resources Bernhard, Peterson (1998),
Moynihan (1998), Poy (1993),
Wilcox (2001)
Data cannot be retrieved later
(this point should be made at
training so that staff
understand the importance of
adhering to PRO assessment
time windows)
1 Requires time and resources Cella (1995)
Good clinical practice/good
research practice
1 Requires time and resources Poy (1993)
Informed consent (PRO issues
to discuss at consent stage)
2 Requires time and resources Little, Cohen (2012),
Wisniewski (2006)
Missing PRO data/importance
of compliance
6 Requires time and resources Fairclough (2010), Little,
Cohen (2012), Luo (2008),
Meyer (2009), Moinpour
Continued
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Table 3 Continued
Category Topic Specific recommendation
N
recommendations* Potential drawbacks
Source/s: first author (year).
Full citations are provided
as Online Supplementary
Appendix C
(1998), Young T, de Haes
(1999)
Purpose/importance of PRO
assessments
12 Requires time and resources Calvert (2004), Cella (1994),
Cella (1995), Hahn (1998),
Hopwood (1998), Little,
D’Agostino (2012), Moinpour
(1998), Poulter (1997),
Taphoorn (2010), Walker
(2003), Young, de Haes
(1999), Young, Maher (1999)
Standardised procedures
(importance of using
standardised methods to
administer PROs to minimise
risk of bias)
8 Requires time and resources Bernhard, Peterson (1998),
Chassany (2002), Friedman
(1998), Hayden (1993), Hurny
(1992), Moinpour (1989),
Sadura (1992), Sloan (2007)
Format of training Informational newsletters (as
an additional training format)
1 Requires time and resources Moinpour (1989)
Pilot study as a training
exercise in administering PROs
and addressing common
problems
1 Requires time, costs and
resources
Cella (1994)
Video training (format) 3 Requires time and resources Bernhard, Cella (1998),
Hayden (1993), Revicki
(2005)
Timing of training Requisite training for site
coordinators (All site
coordinators should receive
training about PROs before
they can work on studies with
PROs.)
4 Requires time and resources Moinpour (1990), Sadura
(1992), Wisniewski (2006)
Training at the start-up
presentation (which can
address study-specific PRO
issues as well as general PRO
issues)
2 Requires time and resources Fallowfield (1998), Fairclough
(2010)
Train clinician
investigators
6 Requires time and resources Hahn (1998), Aaronson
(1990), Poy (1993), Young, de
Haes (1999)
*Some sources may have provided a recommendation more than once.
GP, general practitioner; PRO, patient-reported outcome; QA, quality assurance.
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Table 4 Strategies for reporting studies with missing patient-reported outcome (PRO) data to minimise the potential for biased interpretation of findings
Category Topic Specific recommendation
N
recommendations*
Potential
drawbacks
Source/s: first author (year). Full
citations are provided as Online
Supplementary Appendix C
Reporting—trial
reports enable
readers to interpret
the possible impact
of missing PRO data
on findings
Report PRO data collection
methods (these may shed
light on strategies used to
minimise, or potential
relationships with, missing
PRO data)
Mode of administration of
PROs
1 None—however,
level of detail must
be balanced with
word limit
restrictions.
Revicki (2007)
Staff training 1 None—however,
level of detail must
be balanced with
word limit
restrictions.
Revicki (2007)
Participant training/education 1 None—however,
level of detail must
be balanced with
word limit
restrictions.
Revicki (2007)
Study power calculation and
power achieved for the PRO
analysis (Has missing data
led to substantial loss of
power for PRO analyses?)
1 None Revicki (2007)
Report analysis methods used PRO analysis methods 2 None—however,
level of detail must
be balanced with
word limit
restrictions.
Bernhard, Cella (1998), Revicki
(2005)
Assumptions of PRO
analyses, including
assumptions about missing
PRO data
2 None—however,
level of detail
provided must be
balanced with word
limit restrictions.
Bell (2014), Revicki (2005)
How missing PRO data was
handled for the analysis
9 None Calvert (2013), Chassany (2002),
Machin (1998), Machin (1998),
Noyez (2011), Revicki (2005),
Staquet (1996)
Sensitivity analyses (How has
missing data impacted the
findings?)
2 None—however,
level of detail must
be balanced with
word limit
restrictions.
Bell (2014), Revicki (2005)
Continued
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Table 4 Continued
Category Topic Specific recommendation
N
recommendations*
Potential
drawbacks
Source/s: first author (year). Full
citations are provided as Online
Supplementary Appendix C
Describe the sample Clinical and demographic
characteristics, including
baseline PRO scores
5 None Hewitt (2010), Noyez (2011),
Revicki (2005)
Compare participants with and
without missing data
4 None—however,
level of detail
provided must be
balanced with word
limit restrictions.
Dumville (2006), Hewitt (2010),
Sprangers (2002), Revicki (2005)
Flow diagram (for PRO study),
including rates and reasons
for non-completion
1 None—however,
level of detail must
be balanced with
word limit
restrictions
Revicki (2005)
Report missing data details Compliance definitions (What
was considered a missing
response? How was PRO
assessment compliance
measured?)
1 None—however,
level of detail must
be balanced with
word limit
restrictions.
Lee (2000)
Report the expected PRO
completion rate (number of
participants alive and on the
study per time point)70
3 None Bernhard (1998), Lee (2000),
Revicki (2007)
Report rates of missing PRO
data
26 None Bell (2014), Bernhard, Cella (1998),
Calvert (2013), Chassany (2002),
Fallowfield (2005), Flores (2004),
Kaasa (2002), Lee (2000), Luo
(2008), Machin (1998), Noyez
(2011), Revicki (2005), Revicki
(2007), Staquet (1996), Walker
(2003)
Report reasons for/type of
missing PRO data
15 None—however,
level of detail
provided must be
balanced with word
limit restrictions
Bernhard, Cella (1998), Calvert
(2013), Chassany (2002), Deo
(2011), Fallowfield (2005), Flores
(2004), Lee (2000), Macefield
(2013), Machin (1998), Noyez
(2011), Revicki (2007), Sprangers
(2002), Staquet (1996), Walker
(2003)
Potential bias due to
non-response/impact on
generalisability
Authors should consider and
report how missing data
may have impacted the
generalisability of findings.
6 None—however,
level of detail must
be balanced with
word limit
restrictions.
Bell (2013), Klee (1999), Machin
(1998), Revicki (2005)
*Some sources may have provided a recommendation more than once.
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communication with poorly performing sites led to
reductions in rates of missing baseline PROs. Many trial
groups have reported success of centralised monitoring
systems for maintaining high PRO completion
rates.29 35–37
Staff should have access to ongoing training and written
guidance, and should understand the importance of
PROs.5 26 32 34 37–42 The National Cancer Institute of
Canada Clinical Trials Group (NCIC CTG) has attributed
high PRO completion rates to training the trial team
about the importance of avoiding missing PRO data.43
Patient engagement is also crucial. Hellard et al44 found
that sending participants’ study updates was the primary
reason for high-level participant engagement and reten-
tion, and weekly study diary completion rates of 90.7%
over 68 weeks. All of these recommendations require
intensive resources45 46 and research team commitment,47
and highlight the importance of conducting appropriate
feasibility checks before activating the study. Research
investigators, sponsors and funding bodies have a responsi-
bility to ensure research funds are allocated to quality
assurance of PRO studies. Training regarding the import-
ance and efﬁcacy of speciﬁc quality assurance strategies
may be the catalyst to securing such funding.
Rouette et al48 found that 86% of clinicians surveyed
considered missing data important in interpreting PRO
ﬁndings, and that clinicians require clear summaries
and recommendations for accurate interpretation of
trial results. Clear and sufﬁcient information should be
reported, so readers can meaningfully interpret the pos-
sible impact (bias) of missing PRO data on ﬁndings,
which is crucial for PROs to impact patient care. This
involves reporting descriptions of the study sample,
including baseline PRO scores; rates and reasons for
missing PRO data; analysis methods, including sensitivity
analyses and analysis assumptions, handling of missing
data, and discussing the potential impact of missing data
on PRO ﬁndings. These reporting recommendations are
also addressed in the CONsolidated Standards of
Reporting Trials (CONSORT) PRO extension, under-
scoring their importance to transparency of reporting.49
Systematic reviews have highlighted that methods for
handing missing PRO data are often incorrectly or
simply not applied,10 14 and the extent and handling of
missing PRO data is often unreported.8 10 49–51 These
omissions may hinder the reader from being able to
interpret the impact of missing data on ﬁndings. Journal
editors should enforce reporting guidance such as
CONSORT-PRO49 in order to promote and maintain a
high standard of research evidence. A recent study
found that 31% of reviewed RCTs failed to report PRO
results despite including PRO endpoints in the trial
protocol.52 The authors could not determine reasons
why the RCTs failed to report PROs; however, high rates
of missing data have discouraged investigators from pub-
lishing PRO ﬁndings previously.11 This represents a
waste of research resources, participants’ time and
limited research funding as PRO ﬁndings left
unreported cannot impact patient care.53 Trial registra-
tion and publication of research protocols is a motion
towards avoiding such examples of publication bias;
however, further action towards improving the quality of
PRO data is needed, beginning with more comprehen-
sive training about PROs for all research staff. Thus,
there is an urgent need for research teams to implement
the described strategies to minimise missing PRO data
and when missing data are present, to reduce its impact
on the quality and dissemination of results.
Strengths
The literature on missing PRO data largely comprises
statistically technical material that may be inaccessible
for non-statisticians. We have summarised the problems
created by missing PRO data in a format accessible to
anyone involved in designing, conducting or analysing a
clinical study. In response to the need for all members
of the research team to assist in minimising the problem
of missing data, we have provided the ﬁrst systematic
review to collate practical strategies to minimise the
problem of missing PRO data. A comprehensive search
strategy was used, developed with assistance from ﬁeld
experts and librarians. The review includes recommen-
dations from a substantially large number of sources
from various health disciplines. Many were discussion
pieces written by highly regarded and experienced PRO
experts based on strategies that their trials group or
organisations have implemented, with documented
improvement in PRO completion rates. This review,
therefore, brings together the collective wisdom of
experienced opinion leaders in the ﬁeld. Further, most
recommendations are generalisable across disciplines.
Patterns and similarities in the recommendations
extracted, as well as emerging ﬁndings of ongoing work
investigating causes of missing PRO data,54 provide evi-
dence of their effectiveness in preventing and addres-
sing the missing PRO data problem.
Limitations
As the majority of papers included in our systematic
review were discussion or guidance pieces rather than
original research reports, we were unable to apply study
quality criteria used in traditional systematic reviews to
the source papers. However, we did consider potential
limitations of each recommendation, which is useful
information for researchers considering implementing
these strategies. Further, we have cited the frequency of
each recommendation. High frequency may indicate
widespread use and effectiveness, although we do
acknowledge that some less-cited strategies may also be
highly effective, and some strategies may only apply to
speciﬁc disease or research contexts. Gathering empir-
ical evidence as to the degree of effectiveness of the
strategies identiﬁed in this review would be an interest-
ing direction for future research.
Despite our efforts in extensively hand-searching refer-
ence lists and citing articles, it is possible that relevant
44 Mercieca-Bebber R, et al. BMJ Open 2016;6:e010938. doi:10.1136/bmjopen-2015-010938
Open Access
group.bmj.com on October 14, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
sources and/or recommendations were missed. We
restricted our database search to MEDLINE and
CINAHL databases, and excluded non-English sources.
Searching of non-English language databases may have
identiﬁed additional publications; however, since many
themes were identiﬁed by numerous sources, we do not
believe that this would signiﬁcantly affect our ﬁnd-
ings.55 56 Coding of recommendations was a subjective
process and, as with all qualitative approaches, is subject
to interpretation of the analysts; however, rounds of
code checking ensured the original meaning of recom-
mendations was retained as far as possible.
This paper discusses one aspect of PRO data quality:
data completeness. Many other factors contribute to high-
quality PRO data, such as clinical and psychometric appro-
priateness of PRO measures (valid, reliable, responsive),
compliance with time windows, and ensuring that patients
self-complete.57 Likewise, many factors can contribute to
invalid interpretation of PRO data, including multiple
hypothesis testing57 and clinical versus statistical signiﬁ-
cance.58 59 Some of these issues have been addressed in
the context of missing data in this review, but are inde-
pendently crucial PRO assessment concerns. Readers are
directed to the following sources for further guidance on
PRO study design,57 protocol development,60 61 ana-
lysis17 57 and reporting49 62 of PRO studies.
Implications
We recommend that all members of the research team
involved in designing, collecting, analysing and reporting
PRO data implement the strategies outlined in this review
to minimise the problem of missing PRO data. Missing
PRO data are preventable in many cases through rigorous
study design and methodology. Further guidance on PRO-
speciﬁc content of trial protocols is required, and is cur-
rently under development in the form of a Standard
Protocol Items for Clinical Trials (SPIRIT)-PRO exten-
sion.63 Signiﬁcant funding, and staff and participant time
is invested in PRO studies. Poorly conducted PRO studies
with high rates of preventable missing data yield poor
quality evidence. Funding organisations and sponsors
should actively promote high-quality PRO research by
mandating PRO training for research team members, and
publication of PRO ﬁndings (adhering to CONSORT
PRO extension where applicable) to optimise the value of
PRO data and avoid research waste.53 63
However, we acknowledge that in some health settings,
missing PRO data are not avoidable due to deteriorating
health status of the participants. We have also outlined
strategies that may assist statisticians to appropriately
handle unavoidable missing PRO data to minimise bias.
Again, transparent and complete reporting of missing
PRO data and analysis methods, as described in this
review, will promote valid interpretation of PRO ﬁndings
and assist investigators to make better-informed recom-
mendations for patient care, policy and therapeutic
labelling.
CONCLUSION
It is essential that all researchers involved in design,
conduct, analysis and reporting of PRO data appreciate
why missing data is a problem, why in many circum-
stances statistical methods for handling missing data are
not failsafe, and how all members of the research team
can assist in minimising the problem of missing PRO
data, so that misunderstandings do not become a
barrier to achieving the highest possible PRO comple-
tion rates. To not do so represents a great waste of
research resources and valuable PRO evidence. Careful
planning of PRO studies can minimise the risk and
problem of missing PRO data. Ongoing quality assur-
ance and team commitment throughout study imple-
mentation is also essential, which may be facilitated by
involvement of PRO experts and sponsors. Despite the
existence of missing PRO data, it is possible to make
valid conclusions about the effect of disease and treat-
ment on the patient if missing data are appropriately
handled and analysed, and transparently reported.
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